EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions

Roeland Lameris iD, Adam Shahine, Myrthe Veth, Bart Westerman, Dale I Godfrey, David Lutje Hulsik, Patricia Brouwer, Jamie Rossjohn, Tanja D de Gruijl, Hans J van der Vliet

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2023-007631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Roeland Lameris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Hepatitis A Virus Cellular Receptor 2, Single-Domain Antibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LAVA Therapeutics, NHMRC, ARC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD1d is a monomorphic major histocompatibility complex class I-like molecule that presents lipid antigens to distinct T-cell subsets and can be expressed by various malignancies. Antibody-mediated targeting of CD1d on multiple myeloma cells was reported to induce apoptosis and could therefore constitute a novel therapeutic approach.

Methods

To determine how a CD1d-specific single-domain antibody (VHH) enhances binding of the early apoptosis marker annexin V to CD1d + tumor cells we use in vitro cell-based assays and CRISPR-Cas9-mediated gene editing, and to determine the structure of the VHH1D17-CD1d(endogenous lipid) complex we use X-ray crystallography.

Results

Anti-CD1d VHH1D17 strongly enhances annexin V binding to CD1d + tumor cells but this does not reflect induction of apoptosis. Instead, we show that VHH1D17 enhances presentation of phosphatidylserine (PS) in CD1d and that this is saposin dependent. The crystal structure of the VHH1D17-CD1d(endogenous lipid) complex demonstrates that VHH1D17 binds the A′-pocket of CD1d, leaving the lipid headgroup solvent exposed, and has an electro-negatively charged patch which could be involved in the enhanced PS presentation by CD1d. Presentation of PS in CD1d does not trigger phagocytosis but leads to greatly enhanced binding of T-cell immunoglobulin and mucin domain containing molecules (TIM)-1 to TIM-3, TIM-4 and induces TIM-3 signaling.

Conclusion

Our findings reveal the existence of an immune modulatory CD1d(PS)-TIM axis with potentially unexpected implications for immune regulation in both physiological and pathological conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis A Virus Cellular Receptor 2Single-Domain AntibodiesHumansPhosphatidylserinesAnnexin A5T-Lymphocyte Subsets

Stichwörter der Autor:innen

Adaptive ImmunityAntibody SpecificityImmunomodulation

Substanzen

Hepatitis A Virus Cellular Receptor 2Single-Domain AntibodiesPhosphatidylserinesAnnexin A5

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.
  • Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.
  • Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • LAVA Therapeutics, Utrecht, The Netherlands.
  • Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

ORCID-Profile: Roeland Lameris

Förderung

  • LAVA Therapeutics
  • NHMRC
  • ARC
  • Worldwide Cancer Research
  • CCA-VICI

Zitieren

APA

Lameris, R., Shahine, A., Veth, M., Westerman, B., Godfrey, D. I., Lutje Hulsik, D., Brouwer, P., Rossjohn, J., de Gruijl, T. D., & van der Vliet, H. J. (2023). Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007631

Vancouver

Lameris R, Shahine A, Veth M, Westerman B, Godfrey DI, Lutje Hulsik D, et al. Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007631

BibTeX
@article{Lameris2023,
  author = {Lameris, Roeland and Shahine, Adam and Veth, Myrthe and Westerman, Bart and Godfrey, Dale I and Lutje Hulsik, David and Brouwer, Patricia and Rossjohn, Jamie and de Gruijl, Tanja D and van der Vliet, Hans J},
  title = {Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2023-007631}
}
Kostenlos starten →